NCT00998049 · OUTCOME

Rate of Failure to Mobilize

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant · Source last updated 2015-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: Duration of apheresis (up to 7 days)

What was measured

The rate of failure to mobilize will be estimated by dividing the number of patients that fail to mobilize by the total number of evaluable patients. A patient is considered a failure if they never achieve 2.5 million CD34 cells/kg.

Groups in this outcome

Plerixafor

Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Plerixafor	39

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Plerixafor	3	Not reported	.006	13	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
.006
upper Limit
13
value
3

denoms

counts
group Id
OG000
value
39
units
Participants

description

dispersion Type

95% Confidence Interval

groups

description
Plerixafor 160mg/kg/dose by IV on days 5-8 Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
id
OG000
title
Plerixafor

param Type

NUMBER

reporting Status

POSTED

time Frame

Duration of apheresis (up to 7 days)

title

Rate of Failure to Mobilize

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice